Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 19823 | 29.31 |
09:33 ET | 21122 | 29.685 |
09:35 ET | 16601 | 29.6459 |
09:37 ET | 5897 | 29.635 |
09:39 ET | 9504 | 29.655 |
09:42 ET | 23494 | 29.845 |
09:44 ET | 6793 | 29.649 |
09:46 ET | 3033 | 29.665 |
09:48 ET | 4137 | 29.615 |
09:50 ET | 3441 | 29.32 |
09:51 ET | 8799 | 29.27 |
09:53 ET | 20532 | 28.91 |
09:55 ET | 23013 | 28.96 |
09:57 ET | 20089 | 28.825 |
10:00 ET | 27856 | 28.7495 |
10:02 ET | 21279 | 28.67 |
10:04 ET | 28175 | 28.8 |
10:06 ET | 9730 | 28.82 |
10:08 ET | 28132 | 28.83 |
10:09 ET | 6234 | 28.87 |
10:11 ET | 15718 | 29.04 |
10:13 ET | 7806 | 29.15 |
10:15 ET | 16481 | 29.226 |
10:18 ET | 7218 | 29.47 |
10:20 ET | 4408 | 29.455 |
10:22 ET | 8913 | 29.53 |
10:24 ET | 3480 | 29.58 |
10:26 ET | 6447 | 29.575 |
10:27 ET | 3304 | 29.615 |
10:29 ET | 5868 | 29.665 |
10:31 ET | 6368 | 29.785 |
10:33 ET | 13088 | 29.855 |
10:36 ET | 5409 | 29.87 |
10:38 ET | 7075 | 29.91 |
10:40 ET | 21315 | 29.74 |
10:42 ET | 11013 | 29.81 |
10:44 ET | 6169 | 29.95 |
10:45 ET | 2500 | 29.97 |
10:47 ET | 6213 | 29.87 |
10:49 ET | 6368 | 29.77 |
10:51 ET | 4631 | 29.8 |
10:54 ET | 15398 | 29.845 |
10:56 ET | 3335 | 29.86 |
10:58 ET | 23084 | 29.92 |
11:00 ET | 7307 | 29.825 |
11:02 ET | 16912 | 29.775 |
11:03 ET | 11497 | 29.81 |
11:05 ET | 10550 | 29.79 |
11:07 ET | 7425 | 29.85 |
11:09 ET | 10408 | 29.825 |
11:12 ET | 4787 | 29.78 |
11:14 ET | 11796 | 29.7 |
11:16 ET | 14499 | 29.695 |
11:18 ET | 5837 | 29.67 |
11:20 ET | 6329 | 29.64 |
11:21 ET | 7722 | 29.595 |
11:23 ET | 12621 | 29.555 |
11:25 ET | 9154 | 29.56 |
11:27 ET | 16354 | 29.56 |
11:30 ET | 18669 | 29.63 |
11:32 ET | 21525 | 29.79 |
11:34 ET | 11373 | 29.755 |
11:36 ET | 8292 | 29.64 |
11:38 ET | 8515 | 29.665 |
11:39 ET | 7650 | 29.7 |
11:41 ET | 6776 | 29.67 |
11:43 ET | 4519 | 29.66 |
11:45 ET | 14744 | 29.65 |
11:48 ET | 15463 | 29.57 |
11:50 ET | 6531 | 29.5678 |
11:52 ET | 12579 | 29.4418 |
11:54 ET | 9224 | 29.405 |
11:56 ET | 8289 | 29.375 |
11:57 ET | 8198 | 29.28 |
11:59 ET | 9521 | 29.28 |
12:01 ET | 9003 | 29.2 |
12:03 ET | 5613 | 29.2 |
12:06 ET | 5285 | 29.17 |
12:08 ET | 16876 | 29.2399 |
12:10 ET | 10820 | 29.23 |
12:12 ET | 8005 | 29.26 |
12:14 ET | 20176 | 29.35 |
12:15 ET | 3700 | 29.39 |
12:17 ET | 5843 | 29.32 |
12:19 ET | 8605 | 29.33 |
12:21 ET | 7907 | 29.325 |
12:24 ET | 7076 | 29.41 |
12:26 ET | 3761 | 29.44 |
12:28 ET | 6711 | 29.415 |
12:30 ET | 1873 | 29.43 |
12:32 ET | 9270 | 29.36 |
12:33 ET | 6368 | 29.385 |
12:35 ET | 1168 | 29.385 |
12:37 ET | 10151 | 29.34 |
12:39 ET | 9340 | 29.36 |
12:42 ET | 4001 | 29.335 |
12:44 ET | 14326 | 29.35 |
12:46 ET | 17483 | 29.3 |
12:48 ET | 11023 | 29.2 |
12:50 ET | 5332 | 29.19 |
12:51 ET | 29963 | 29.29 |
12:53 ET | 1275 | 29.285 |
12:55 ET | 3041 | 29.22 |
12:57 ET | 7524 | 29.31 |
01:00 ET | 3280 | 29.3 |
01:02 ET | 8490 | 29.33 |
01:04 ET | 10792 | 29.265 |
01:06 ET | 8799 | 29.295 |
01:08 ET | 12821 | 29.35 |
01:09 ET | 4724 | 29.31 |
01:11 ET | 4000 | 29.33 |
01:13 ET | 10937 | 29.23 |
01:15 ET | 6211 | 29.19 |
01:18 ET | 16785 | 29.22 |
01:20 ET | 9560 | 29.26 |
01:22 ET | 13042 | 29.3 |
01:24 ET | 7363 | 29.27 |
01:26 ET | 8425 | 29.265 |
01:27 ET | 14395 | 29.22 |
01:29 ET | 4857 | 29.2438 |
01:31 ET | 7154 | 29.29 |
01:33 ET | 9989 | 29.38 |
01:36 ET | 6965 | 29.35 |
01:38 ET | 4572 | 29.38 |
01:40 ET | 9407 | 29.4 |
01:42 ET | 8074 | 29.4 |
01:44 ET | 8002 | 29.35 |
01:45 ET | 8028 | 29.33 |
01:47 ET | 6529 | 29.395 |
01:49 ET | 9509 | 29.369 |
01:51 ET | 7370 | 29.395 |
01:54 ET | 4540 | 29.41 |
01:56 ET | 8701 | 29.47 |
01:58 ET | 18347 | 29.54 |
02:00 ET | 5014 | 29.51 |
02:02 ET | 12010 | 29.495 |
02:03 ET | 7300 | 29.425 |
02:05 ET | 7761 | 29.4486 |
02:07 ET | 2914 | 29.54 |
02:09 ET | 5847 | 29.5055 |
02:12 ET | 13987 | 29.43 |
02:14 ET | 5661 | 29.395 |
02:16 ET | 14039 | 29.33 |
02:18 ET | 3774 | 29.31 |
02:20 ET | 7673 | 29.46 |
02:21 ET | 11549 | 29.4 |
02:23 ET | 4245 | 29.36 |
02:25 ET | 4250 | 29.37 |
02:27 ET | 17729 | 29.37 |
02:30 ET | 5926 | 29.41 |
02:32 ET | 7037 | 29.38 |
02:34 ET | 5315 | 29.37 |
02:36 ET | 10134 | 29.37 |
02:38 ET | 6140 | 29.39 |
02:39 ET | 6523 | 29.5 |
02:41 ET | 12013 | 29.4501 |
02:43 ET | 10627 | 29.51 |
02:45 ET | 8921 | 29.485 |
02:48 ET | 5002 | 29.5067 |
02:50 ET | 10908 | 29.52 |
02:52 ET | 9491 | 29.575 |
02:54 ET | 6600 | 29.55 |
02:56 ET | 7157 | 29.56 |
02:57 ET | 2866 | 29.58 |
02:59 ET | 9985 | 29.605 |
03:01 ET | 15598 | 29.58 |
03:03 ET | 13657 | 29.63 |
03:06 ET | 6757 | 29.62 |
03:08 ET | 10026 | 29.67 |
03:10 ET | 11634 | 29.67 |
03:12 ET | 4804 | 29.7 |
03:14 ET | 6590 | 29.73 |
03:15 ET | 12057 | 29.69 |
03:17 ET | 12167 | 29.735 |
03:19 ET | 8061 | 29.755 |
03:21 ET | 8388 | 29.7977 |
03:24 ET | 11589 | 29.76 |
03:26 ET | 5967 | 29.7865 |
03:28 ET | 10087 | 29.78 |
03:30 ET | 10923 | 29.77 |
03:32 ET | 10230 | 29.73 |
03:33 ET | 8001 | 29.7 |
03:35 ET | 21285 | 29.585 |
03:37 ET | 23091 | 29.6196 |
03:39 ET | 8761 | 29.64 |
03:42 ET | 16692 | 29.65 |
03:44 ET | 14055 | 29.74 |
03:46 ET | 10304 | 29.75 |
03:48 ET | 14301 | 29.67 |
03:50 ET | 12545 | 29.65 |
03:51 ET | 22772 | 29.57 |
03:53 ET | 37104 | 29.69 |
03:55 ET | 40052 | 29.62 |
03:57 ET | 38187 | 29.65 |
04:00 ET | 541602 | 29.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 4.6B | -277.6x | --- |
ADMA Biologics Inc | 4.5B | 70.7x | --- |
Axsome Therapeutics Inc | 4.5B | -14.1x | --- |
Arcellx Inc | 4.7B | -122.6x | --- |
Blueprint Medicines Corp | 5.6B | -42.8x | --- |
CRISPR Therapeutics AG | 4.0B | -16.9x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6B |
---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.19 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -277.6x |
Price/Sales (TTM) | 17.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.